Skip to main content

Table 2 Correlation between ADAM10 expression and clinic pathological factors in 94 breast cancer tissues

From: ADAM10 is involved in the oncogenic process and chemo-resistance of triple-negative breast cancer via regulating Notch1 signaling pathway, CD44 and PrPc

Factors ADAM10 expression Univariate analysis Multivariate analysis
Low (mean ± SE) High (mean ± SE) p-value OR (95%CI) p-value OR (95%CI) p-value
Age at diagnosis (years)
 < 55 34 (120.4 ± 54.60) 15 (252.0 ± 34.58) 0.008** 0.35 (0.12–1.00) 0.050 0.96 (0.19–4.77) 0.963
 ≥ 55 39 (91.2 ± 62.02) 6 (297.5 ± 6.12)      
Menopause
Yes 53 (98.9 ± 62.35) 10 (277.5 ± 27.61) 0.024* 0.34 (0.13–0.93) 0.036* 0.45 (0.05–0.53) 0.292
No 20 (120.5 ± 51.9) 11 (253.6 ± 39.94)      
BMI (kg/m2)
 > 23 51 (106.7 ± 56.50) 6 (245.0 ± 37.55) 0.023* 5.80 (1.99–16.91) 0.001** 0.17 (0.10–2.00) 0.002**
 ≤ 23 22 (100.5 ± 68.97) 15 (273.0 ± 33.16)      
Histological grade
I 4 (95.0 ± 72.23) 2 (262.5 ± 53.03) 0.172 0.55 (0.18–1.65) 0.286   
II 56 (98.4 ± 59.23) 17 (270.0 ± 34.37)      
III 13 (135.4 ± 55.28) 2 (225.0 ± 21.21)      
Tumor size
T1 4 (78.8 ± 55.43) 2 (262.5 ± 53.03) 0.683 0.89 (0.29–2.76) 0.846   
T2 60 (104.8 ± 62.52) 16 (266.3 ± 37.35)      
T3 9 (116.1 ± 45.26) 3 (260.0 ± 31.22)      
Distant metastasis (before NACT)
Yes 4 (107.5 ± 70.77) 3 (300) 0.287 0.56 (0.06–4.92) 0.599   
No 53 (109.7 ± 63.91) 16 (282.2 ± 21.37)      
Regional lymphatic metastasis (after NACT)
Yes 38 (103.3 ± 62.63) 9 (283.3 ± 21.79) 0.066 1.42 (0.52–3.83) 0.492   
No 19 (122.1 ± 65.77) 10 (286.5 ± 20.55)      
Response to NACT
Good 58 (99.5 ± 59.41) 11 (285 ± 27.66) 0.023* 0.28 (0.10–0.79) 0.016* 0.29 (0.44–16.22) 0.042*
Poor 15 (125.3 ± 60.34) 10 (243.0 ± 31.46)      
  1. OR odds ratio, CI confidence interval
  2. *p < 0.05, **p < 0.01